Kemtai

Kemtai
AI-powered personalized home fitness trainer that provides real-time guidance and feedback.
About
What does Kemtai do?
Kemtai provides a motion tracking exercise platform powered by computer vision AI for physical therapy and fitness. It enables healthcare systems, payers, digital health platforms, and rehab centers to improve patient adherence, reduce costs, and scale rehabilitation services through scientifically validated accuracy and data solutions. The platform offers features like range of motion tracking, digital assessments, and guided exercise sessions.
Where is Kemtai headquartered?
Kemtai is headquartered in Tel Aviv, Israel.
When was Kemtai founded?
Kemtai was founded in 2019.
What industry does Kemtai operate in?
Kemtai operates in Fitness, Trainer, HealthTech, Fitness Tech, Computer Vision, AI Tool.
How many employees does Kemtai have?
Kemtai has approximately 7 people on record.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Purpose-built WordPress plugins for healthcare and the agencies that serve them.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 6 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.
